Lyso-Gb3 levels were somewhat higher in ADA-positive (101.6 ± 13.7 ng/ml) than in ADA-negative (55.2 ± 20.1 ng/ml) FD patients before (Figure 3I: p=0.07) but not after ERT initiation (35.8 ± 7.2 ng/ml vs. 19.7 ± 7.1 ng/ml) (Figure 3J). The gene discussed is ADA; the disease is Fabry disease.